Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.85 |
| ▸ | JAK2 | O60674 | 4/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | TEC | P42680 | 1/20 | 0.57 |
| ▸ | TXK | P42681 | 1/20 | 0.57 |
| ▸ | BLK | P51451 | 1/20 | 0.57 |
| ▸ | BMX | P51813 | 1/20 | 0.57 |
| ▸ | CD69 | Q07108 | 1/20 | 0.57 |
| ▸ | ITK | Q08881 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19690340 | 1.00 | BTK (0.85) | BTKJAK2LCKCYP3A4CYP2C8 | |
| SCHEMBL19690375 | 0.92 | BTK (0.82) | BTKJAK2LCKCYP3A4CYP2C8 | |
| SCHEMBL19690239 | 0.92 | BTK (1.00) | BTK | |
| SCHEMBL19690374 | 0.92 | BTK (0.82) | BTKJAK2LCKCYP3A4CYP2C8 | |
| SCHEMBL19279328 | 0.92 | BTK (1.00) | BTK | |
| SCHEMBL19279030 | 0.87 | BTK (0.65) | BTKJAK2LCKTECTXK | |
| SCHEMBL19690324 | 0.85 | BTK (0.70) | BTKJAK2LCKCYP3A4CYP2C8 | |
| SCHEMBL19690323 | 0.85 | BTK (0.70) | BTKJAK2LCKCYP3A4CYP2C8 | |
| SCHEMBL21837186 | 0.84 | BTK (1.00) | BTK | |
| SCHEMBL21837182 | 0.84 | BTK (1.00) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3209652-B1 | TRICYCLIC ATROPISOMER COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-15 | — | — | EP | disclosed |
| US-10023534-B2 | Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170355673-A1 | TRICYCLIC ATROPISOMER COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355673-A1 | TRICYCLIC ATROPISOMER COMPOUNDS | BTK, LCK, SYK | BTK 1/4885JAK2 6/4885LCK 2/4885 |
| US-10023534-B2 | Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK | BTK, JAK2, SYK | BTK 1/4885JAK2 2/4885LCK 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.